Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Harvard Business School
Mallinckrodt
AstraZeneca
Baxter

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,125,875

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,125,875 protect, and when does it expire?

Patent 7,125,875 protects SPRYCEL and is included in one NDA.

Protection for SPRYCEL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-seven patent family members in thirty-eight countries.

Summary for Patent: 7,125,875
Title:Cyclic protein tyrosine kinase inhibitors
Abstract:Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
Inventor(s): Das; Jagabandhu (Mercerville, NJ), Padmanabha; Ramesh (Hamden, CT), Chen; Ping (Belle Mead, NJ), Norris; Derek J. (Trenton, NJ), Doweyko; Arthur M. P. (Long Valley, NJ), Barrish; Joel C. (Richboro, PA), Wityak; John (Robbinsville, NJ), Lombardo; Louis J. (Belle Mead, NJ), Lee; Francis Y. F. (Yardley, PA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:10/395,503
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,125,875
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,125,875

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-001 Jun 28, 2006 RX Yes No   Start Trial   Start Trial Y   Start Trial
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-002 Jun 28, 2006 RX Yes No   Start Trial   Start Trial Y   Start Trial
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-003 Jun 28, 2006 RX Yes No   Start Trial   Start Trial Y   Start Trial
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-005 Oct 28, 2010 RX Yes No   Start Trial   Start Trial Y   Start Trial
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-004 May 30, 2008 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-006 Oct 28, 2010 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,125,875

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 044506   Start Trial
Austria 464898   Start Trial
Australia 2004223828   Start Trial
Australia 4233800   Start Trial
Australia 779089   Start Trial
Brazil 0009721   Start Trial
Brazil PI0009721   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Harvard Business School
Moodys
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.